← All trials
NCT03413306
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2016
- Primary completion
- Dec 20, 2019
- Completion date
- Dec 20, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyLead sponsor
- Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and ImmunologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.